Patrick Machado - 21 May 2025 Form 4 Insider Report for ALUMIS INC. (ALMS)

Role
Director
Signature
/s/ Sara Klein, Attorney-in-Fact
Issuer symbol
ALMS
Transactions as of
21 May 2025
Net transactions value
$0
Form type
4
Filing time
23 May 2025, 16:05:20 UTC
Previous filing
27 Jun 2024
Next filing
06 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Machado Patrick Director C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO /s/ Sara Klein, Attorney-in-Fact 23 May 2025 0001311210

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALMS Common Stock Award +7,064 7,064 21 May 2025 By Trust F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALMS Stock Option (Right to Buy) Award +44,364 44,364 21 May 2025 Class A Common Stock 44,364 $9.26 Direct F1, F3, F4, F5
transaction ALMS Stock Option (Right to Buy) Award +11,189 11,189 21 May 2025 Class A Common Stock 11,189 $37.39 Direct F1, F4, F5, F6
transaction ALMS Stock Option (Right to Buy) Award +41,499 41,499 21 May 2025 Class A Common Stock 41,499 $12.21 Direct F1, F4, F5, F7
transaction ALMS Stock Option (Right to Buy) Award +13,804 13,804 21 May 2025 Class A Common Stock 13,804 $12.21 Direct F1, F4, F5, F8
transaction ALMS Stock Option (Right to Buy) Award +19,528 19,528 21 May 2025 Class A Common Stock 19,528 $1.60 Direct F1, F4, F5, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 6, 2025, the Issuer entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with ACELYRIN, Inc., a Delaware corporation ("ACELYRIN"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into ACELYRIN (the "Merger"), with ACELYRIN surviving as a wholly owned subsidiary of Issuer. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of ACELYRIN issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Issuer, par value $0.0001 per share, and cash in lieu of any fractional shares.
F2 Shares held directly by Patrick Machado Revocable Trust, Patrick Machado, TEE, for which the Reporting Person serves as trustee.
F3 Received in the Merger in exchange for an employee stock option to acquire 92,158 shares of ACELYRIN common stock for $4.46 per share.
F4 Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Issuer and converted into an option to purchase a number of shares of Issuer Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding ACELYRIN stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F5 Stock Option is fully vested and exercisable.
F6 Received in the Merger in exchange for an employee stock option to acquire 23,243 shares of ACELYRIN common stock for $18.00 per share.
F7 Received in the Merger in exchange for an employee stock option to acquire 86,206 shares of ACELYRIN common stock for $5.8766 per share.
F8 Received in the Merger in exchange for an employee stock option to acquire 28,675 shares of ACELYRIN common stock for $5.8766 per share.
F9 Received in the Merger in exchange for an employee stock option to acquire 40,567 shares of ACELYRIN common stock for $0.7683 per share.